Protara Therapeutics, Inc. Common Stock

TARANASDAQ • USD
ThemeHealthcare - Oncology›Cell & Gene Therapy for Cancer
4.16 USD
↘ 0.25 (5.67%)AT CLOSE (11:59 AM EDT)
4.17
↗ 0.01 (0.12%)
POST MARKET (AS OF 06:52 PM EDT)
Post Market
AS OF 06:52 PM EDT
4.17
↗ 0.01 (0.12%)
🔴Market: CLOSED
Open?$4.43
High?$4.43
Low?$4.14
Prev. Close?$4.41
Volume?442.5K
Avg. Volume?711.3K
VWAP?$4.24
Rel. Volume?0.62x
Bid / Ask
Bid?$3.55 × 100
Ask?$5.01 × 100
Spread?$1.46
Midpoint?$4.28
Valuation & Ratios
Market Cap?233.8M
Shares Out?56.2M
Float?45.9M
Float %?88.8%
P/E Ratio?N/A
P/B Ratio?1.29
EPS?-$1.13
Dividend?0.00%
Ex-Dividend?N/A

Protara Therapeutics, Inc. Common Stock (TARA) is currently trading at $4.16. Technicals currently rate "Strong Sell" while our fundamental analysis reads "Neutral". Notable factors include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.

Technical & fundamental data as of Jun 5, 2026.

News
Profile
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.
Themes
Healthcare - Oncology›Cell & Gene Therapy for CancerBiotech - Drug Development›Rare Disease Therapeutics
Employees
51
Market Cap
233.8M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
www.protaratx.com
Listed
2020-01-10
Address
345 PARK AVENUE SOUTH
NEW YORK, NY 10010
Phone: 646-844-0337
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
50
Short Sent.?
50
Piotroski F-Score?0/9Weak
Altman Z-Score?10.37Safe
Confidence?40%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?8.15%Elevated
Short Interest?3.7M
Days to Cover?5.6
Free Float45.9M
Avg Daily Volume666.0K
Settlement Date2026-05-15
Financial Health
Current Ratio?15.69Strong
Quick Ratio?15.69Strong
Cash Ratio?1.65Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
91
1.29CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-3.1CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
5
-34.9%WEAK▾
ROA?
S&P
3
-33.0%WEAK▾
Cash Flow & Enterprise
FCF?$-63045000
Enterprise Value?$219.1M
Fundamentals ratios updated end of day
MarketsMoversWatchlist